Oncology products comprise more than 20 percent of the total pharmaceutical pipeline. At the same time, cancer treatment remains among the costliest therapies. It's no wonder, then, that payers continue to explore new avenues for reducing spending in this broad disease category--all the while working to avoid the negative publicity that comes with limiting treatment options for cancer patients.
Join us on Tuesday, June 22 at 2:00PM (Eastern) for the third presentation in our five-part webcast series, "Ensuring Patient Access to Products in the Evolving Healthcare Market." In part three, Elizabeth Hackney Davies, Assistant Director for Xcenda, and Ken Trader, Vice President of Business Development for AmerisourceBergen Specialty Group, discuss what payers are currently exploring to increase cost efficiencies in cancer care--and what manufacturers can expect moving forward.
Discussion topics include:
PRESENTERS
Elizabeth Hackney Davies, MHA
Assistant Director
Xcenda
Ken Trader
Vice President, Business Development
AmerisourceBergen Specialty Group